Entries |
Document | Title | Date |
20080207577 | Combination I - The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a P2X | 08-28-2008 |
20080221072 | Fatty Acid Modified Forms of Glucocorticoids - Compounds are disclosed of the formula | 09-11-2008 |
20080255073 | COMPOUNDS FOR SUSTAINED RELEASE OF ORALLY DELIVERED DRUGS - Disclosed are methods for providing sustained systemic blood concentrations of orally delivered drugs. Still further, disclosed are compounds and pharmaceutical compositions that are used in such methods. | 10-16-2008 |
20080306038 | Compositions and Methods for Modulating Inflammation Using Fluoroquinolones - Compositions for modulating an inflammation comprise a fluoroquinolone having one of Formulae I-VIII. Methods for modulating an inflammation comprise administering such compositions to a subject in need thereof. The compositions and methods are suitable for modulating an ocular or ophthalmic inflammation, including uveitis, vernal keratoconjunctivitis, or inflammation associated with contact lens-associated corneal infiltrates. | 12-11-2008 |
20090048221 | Conjugates with Anti-Inflammatory Activity - Compounds represented by Formula I: | 02-19-2009 |
20090054384 | AIRWAY ALKALINIZATION AS THERAPY FOR AIRWAY DISEASES - The present invention relates to a method of treating asthma by raising the pH of the airways of an individual. The effect can be mediated directly by administering a pharmaceutically acceptable basic solution or alternatively, the effect can be mediated by enhancing the activity of glutaminase. | 02-26-2009 |
20090075959 | DEUTERIUM-ENRICHED CICLESONIDE - The present application describes deuterium-enriched ciclesonide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090075960 | Method of treating gaucher disease - Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof. | 03-19-2009 |
20090082319 | DEUTERIUM-ENRICHED BUDESONIDE - The present application describes deuterium-enriched budesonide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-26-2009 |
20090088411 | No-donating corticosteroid with improved pharmacokinetic, anti-inflammatory and vasodilatory properties - There are herein provided methods of treatment and nitric oxide donating compositions of matter for the treatment of respiratory diseases and associated conditions. | 04-02-2009 |
20090105201 | Pulmonary Pharmaceutical Formulations - The present invention provides improved pharmaceutical formulations for pulmonary delivery having improved chemical and physical stability of the therapeutic, prophylactic or diagnostic agent as compared to formulations known in the art. The improved pharmaceutical formulations of the invention for administration to the respiratory system of a patient for the treatment of a variety of disease conditions comprise a mass of biocompatible particles comprising an active agent, and a hydrogenated starch hydrosylate (HSH). The improvement over the prior art comprises the presence of HSH in the pharmaceutical formulation. The invention further relates to a method of treating diseases comprising administering the pharmaceutical formulations of the present invention to the respiratory system of a patient in need of treatment. | 04-23-2009 |
20090118246 | Therapeutic ophthalmic compositions containing retinal friendly recpients and related methods - Pharmaceutical compositions suitable for administration into the interior of an eye of a person or animal are described. The present compositions include one or more components which are effective in providing a reduced toxicity relative to existing intraocular ophthalmic compositions. The present compositions include one or more therapeutic agents in amounts effective in providing a desired therapeutic effect when placed in an eye, and one or more retinal friendly excipients that have a reduced toxicity relative to benzyl alcohol or polysorbate 80. In certain compositions, the excipient component of the compositions comprises one or more cyclodextrins or cyclodextrin derivatives. Methods of using the compositions to treat ocular conditions are also described. | 05-07-2009 |
20090118247 | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods - Pharmaceutical compositions suitable for administration into the interior of an eye of a person or animal are described. The present compositions include one or more components which are effective in providing a reduced toxicity relative to existing intraocular ophthalmic compositions. The present compositions include one or more therapeutic agents in amounts effective in providing a desired therapeutic effect when placed in an eye, and one or more retinal friendly excipients that have a reduced toxicity relative to benzyl alcohol or polysorbate 80. In certain compositions, the excipient component of the compositions comprises one or more cyclodextrins or cyclodextrin derivatives. Methods of using the compositions to treat ocular conditions are also described. | 05-07-2009 |
20090124586 | Aqueous-based pharmaceutical composition - An aqueous pharmaceutical composition which is capable of being sprayed into the nasal cavity of an individual and which comprises: (A) a pharmaceutically effective amount of solid particles of medicament which is effective in treating a bodily condition by virtue of its being present on the mucosal surfaces of the nasal cavity; and (B) a suspending agent in an amount effective to maintain said particles dispersed uniformly in the composition and to impart to the composition the following thixotropic properties: (i) the viscosity of the position in unsheared form is relatively high, with the composition being in gel-like form; (ii) as the composition is subjected to shear (shaken) in preparation for spraying, the viscosity of the composition becomes relatively low and such that the composition in the form of a mist flows readily into the nasal passages for deposit on the mucosal surfaces of the nasal cavity; and (D) in deposited form on the mucosal surfaces, the viscosity of the composition is relatively high and such that it resists being cleared from the mucosal surfaces by the inherent mucocillary forces which are present in the nasal cavity, a method of use of the composition and a method for preparation of the composition, including in preferred form the use of anti-inflammatory steroid, for example, triamcinoline acetonide, and an odorless form of the composition. | 05-14-2009 |
20090137540 | COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL INFLAMMATION - Provided herein are methods for treating, preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention. | 05-28-2009 |
20090143348 | POLYSACCHARIDE GEL COMPOSITIONS AND METHODS FOR SUSTAINED DELIVERY OF DRUGS - Methods of producing a biocompatible polysaccharide gel composition having sustained release properties are disclosed. Also disclosed is a biocompatible polysaccharide gel composition having sustained release properties, a method of treating a disease or condition using the present biocompatible polysaccharide gel composition, and a method of controlling rate of release of at least one target solute from the biocompatible polysaccharide gel composition. Pharmaceutical compositions which include the present biocompatible polysaccharide gel composition also are disclosed. | 06-04-2009 |
20090149432 | METHODS FOR ADMINISTERING CORTICOSTEROID FORMULATIONS - Described here are methods for the treatment of respiratory conditions using nebulized corticosteroids. The methods administer a dose of corticosteroid twice a day or more with nebulization times of 5 minutes or less. The faster nebulization times improve patient compliance. The methods also employ a lower corticosteroid dose while achieving therapeutic efficacy similar to commercially available formulations. This results in improved patient safety by reducing the systemic exposure of the corticosteroid. | 06-11-2009 |
20090149433 | COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION OF THE GASTROINTESTINAL TRACT - Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention. | 06-11-2009 |
20090156568 | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods - Pharmaceutical compositions suitable for administration into the interior of an eye of a person or animal are described. The present compositions include one or more components which are effective in providing a reduced toxicity relative to existing intraocular ophthalmic compositions. The present compositions include one or more therapeutic agents in amounts effective in providing a desired therapeutic effect when placed in an eye, and one or more retinal friendly excipients that have a reduced toxicity relative to benzyl alcohol or polysorbate 80. In certain compositions, the excipient component of the compositions comprises one or more cyclodextrins or cyclodextrin derivatives. Methods of using the compositions to treat ocular conditions are also described. | 06-18-2009 |
20090163456 | CARBONATE AND CARBAMATE MODIFIED FORMS OF GLUCOCORTICOIDS IN COMBINATION WITH B2 ADRENERGIC AGONISTS - Compositions containing β | 06-25-2009 |
20090163457 | Compositions and methods for delivering a biologically active agent - The invention relates to codrugs having improved properties, methods for preparing and administering them, and methods of formulating and administering the codrugs as pharmaceutical preparations. In certain embodiments, the codrugs can be locally administered to deliver the constituent biologically active compound in a sustained-release fashion, reducing systemic concentrations of the biologically active compound. | 06-25-2009 |
20090197846 | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods - Pharmaceutical compositions suitable for administration into the interior of an eye of a person or animal are described. The present compositions include one or more components which are effective in providing a reduced toxicity relative to existing intraocular ophthalmic compositions. The present compositions include one or more therapeutic agents in amounts effective in providing a desired therapeutic effect when placed in an eye, and one or more retinal friendly excipients that have a reduced toxicity relative to benzyl alcohol or polysorbate 80. In certain compositions, the excipient component of the compositions comprises one or more cyclodextrins or cyclodextrin derivatives. Methods of using the compositions to treat ocular conditions are also described. | 08-06-2009 |
20090197847 | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods - Pharmaceutical compositions suitable for administration into the interior of an eye of a person or animal are described. The present compositions include one or more components which are effective in providing a reduced toxicity relative to existing intraocular ophthalmic compositions. The present compositions include one or more therapeutic agents in amounts effective in providing a desired therapeutic effect when placed in an eye, and one or more retinal friendly excipients that have a reduced toxicity relative to benzyl alcohol or polysorbate 80. In certain compositions, the excipient component of the compositions comprises one or more cyclodextrins or cyclodextrin derivatives. Methods of using the compositions to treat ocular conditions are also described. | 08-06-2009 |
20090203660 | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods - Pharmaceutical compositions suitable for administration into the interior of an eye of a person or animal are described. The present compositions include one or more components which are effective in providing a reduced toxicity relative to existing intraocular ophthalmic compositions. The present compositions include one or more therapeutic agents in amounts effective in providing a desired therapeutic effect when placed in an eye, and one or more retinal friendly excipients that have a reduced toxicity relative to benzyl alcohol or polysorbate 80. In certain compositions, the excipient component of the compositions comprises one or more cyclodextrins or cyclodextrin derivatives. Methods of using the compositions to treat ocular conditions are also described. | 08-13-2009 |
20090221543 | NEW CORTICOSTEROIDS - Nitrooxy derivatives of steroidal compounds of general formula | 09-03-2009 |
20090264391 | Fluocinolone Implants to Protect Against Undesirable Bone and Cartilage Destruction - Effective treatments for protecting against undesirable macrophage activity are provided. Through the administration of an effective amount of fluocinolone at or near a target site, one can reduce or prevent macrophage activity. In various embodiments, fluocinolone formulations may be provided within biodegradable polymers to prevent transplant rejection for at least thirty days. In some embodiments, the relief can be for at least sixty days, or up to ninety days. | 10-22-2009 |
20090264392 | TREATING EOSINOPHILIC ESOPHAGITIS - This document provides methods and compositions suitable for treating eosinophilic esophogitis. For example, this document provides methods that involve administering a steroid and mucoadherent to a mammal (e.g., a human). Kits comprising compositions containing a steroid in combination with a mucoadherent also are provided. | 10-22-2009 |
20090264393 | NITROOXY DERIVATIVES OF GLUCOCORTICOIDS - The invention relates to new steroids nitrooxyderivatives, to topical pharmaceutical formulations thereof, and their use for treating skin or mucosal membrane diseases or disorders. These new steroids nitrooxyderivatives have an improved pharmacological activity and enhanced local tolerability. | 10-22-2009 |
20090264394 | NITROOXY DERIVATIVES OF GLUCOCORTICOIDS - The invention relates to new steroids nitrooxyderivatives, to topical pharmaceutical formulations thereof, and their use for treating skin or mucosal membrane diseases or disorders. These new steroids nitrooxyderivatives have an improved pharmacological activity and enhanced local tolerability. | 10-22-2009 |
20090298803 | PHARMACEUTICAL COMPOSITION COMPRISING FLUOCINONIDE - The present invention provides a composition, comprising fluocinonide in a vehicle comprising one or two penetration enhancers, solvents and emulsifiers wherein penetration enhancers are present in ratio of less than 0.90 to the total of the penetration enhancers, solvents and emulsifiers. | 12-03-2009 |
20090306029 | PROCESS FOR THE PREPARATION OF STERILE POWDERED PHARMACEUTICAL COMPOUNDS - The invention relates to a process for the preparation of pharmaceutical powders, the process comprising: a) solubilization of the pharmaceutical compound in water or in an organic solvent at a concentration close to saturation; b) evaporating the solvent at constant temperature while subjecting the solution to ultrasound. In another embodiment, the invention relates to a process for the preparation of sterile pharmaceutical compounds, the process comprising: a) solubilization of the pharmaceutical compound in water or in an organic solvent at a concentration close to saturation; b) sterilizing filtration of the solution by passing it through a hydrophobic filter (0.22 microns membrane); c) evaporating the solvent at constant temperature while subjecting the solution to ultrasound. | 12-10-2009 |
20100009951 | Ciclesonide containing sterile aqueous suspension - The present invention relates to a sterile aqueous suspension containing ciclesonide, a microgel and a water soluble ionic polymer. The present invention provides a sterile aqueous suspension in which ciclesonide is dispersed homogeneously over a long period of time. | 01-14-2010 |
20100035854 | DRY POWDER FORMULATIONS - A dry powder suitable for inhalation in a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles of magnesium stearate. The invention is also directed to a method of making dry powders by blending together the ingredients mentioned in a diffusion blender for a period time that is less than 60 minutes. | 02-11-2010 |
20100041633 | NITRIC OXIDE RELEASING STEROIDS - The invention relates to nitrooxyderivative of corticosteroids of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereof wherein R is a corticosteroid residue selected from: The compounds are useful in the treatment of respiratory diseases. | 02-18-2010 |
20100048523 | Compounds, Compositions and Methods for Treating Hormone-Dependent Maladies - A composition and method of using are provided, which composition includes: at least one compound selected from the group including a compound having formula (I), a salt thereof, a prodrug thereof, a compound having formula (II), a salt thereof, a prodrug thereof, and a combination thereof, the compounds being described herein, and a combination thereof, and at least one pharmaceutically acceptable carrier; wherein the composition is suitable for administration to a mammal. Methods of using the compound are also provided. | 02-25-2010 |
20100093684 | SYNERGISTIC INTERACTION OF NOTCH-1 INHIBITORS WITH GLUCOCORTICOIDS - The present invention relates to methods and compositions for preventing and/or treating various conditions in a patient, including for example, T-cell lymphoblastic leukemia and lymphoma as well as neurodegenerative diseases, such as for example, Alzheimer's disease. In one preferred embodiment of the invention, such methods include providing a patient with an effective amount of a combination of a NOTCH-1 inhibitor and glucocorticoid. The present invention further encompasses methods for increasing the efficacy of, and mitigating resistance to, glucocorticoids in the treatment of T-cell lymphoblastic leukemia and lymphoma, which generally include providing a patient with an effective amount of one or more NOTCH-1 inhibitors. | 04-15-2010 |
20100093685 | NITRIC OXIDE RELEASING STEROIDS - The invention relates to nitrooxyderivative of corticosteroids of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereof | 04-15-2010 |
20100099653 | Particle Size Reduction Apparatus, and Use Thereof - A sterilisable particle-size reduction apparatus, component parts thereof and a method of sterilising and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs. | 04-22-2010 |
20100168073 | METHOD FOR TREATING AND/OR PREVENTING RETINAL DISEASES WITH SUSTAINED RELEASE CORTICOSTEROIDS - The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from the device. | 07-01-2010 |
20100197646 | SOLVENT-BASED STERILISATION OF PHARMACEUTICALS - A sterile composition of a pharmaceutical compound is prepared by combining solvent with a non-sterile pharmaceutical compound to form a solution and filtering to yield a sterile pharmaceutical compound, optionally removing all or part of the solvent, and under sterile conditions combining the compound with a pharmaceutically acceptable carrier. | 08-05-2010 |
20100222312 | DELAYED-RELEASE GLUCOCORTICOID TREATMENT OF ASTHMA - The present invention refers to the treatment of asthma by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof. | 09-02-2010 |
20100261691 | AMORPHOUS FORM OF AN ANTI-INFLAMMATORY COMPOUND - The invention relates to the technical field of anti-inflammatory compounds, specifically those of a steroid nature, in particular to a new amorphous form of a nitrooxy derivative of a corticosteroid, its pharmaceutical formulations and its use in the treatment or prevention of diseases or symptoms of the skin or mucous membranes. | 10-14-2010 |
20110086827 | COMBINATION MEDICAMENT - The subject matter of this application relates to the combination of ciclesonide or an epimer thereof with R,R-formoterol or a salt, or a hydrate of a salt thereof. | 04-14-2011 |
20110105449 | DRY POWDER FORMULATIONS COMPRISING ASCORBIC ACID DERIVATES - The invention provides dry powder pharmaceutical formulations comprising an ascorbic acid derivative that demonstrate good inhalation performance and dry powder inhalers containing them. | 05-05-2011 |
20110144072 | Antiglucocorticoid Therapy for the Prevention of Neurological Damage in Premature Infants - This invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for preventing neurological damage associated with glucocorticoid therapy in ventilator-dependent low birth weight preterm infants. Mifepristone, a potent glucocorticoid receptor antagonist, can be used in these methods. | 06-16-2011 |
20110144073 | GLUCOCORTICOIDS ATTACHED TO NITRATE ESTERS VIA AN AROMATIC LINKER IN POSITION 21 AND THEIR USE IN OPHTHALMOLOGY - The invention relates to nitrooxy derivatives of fluocinolone acetonide, triamcinolone acetonide, betamethasone and beclomethasone, methods for their preparation, pharmaceutical compositions containing these compounds, and methods of using these compounds and compositions for treating diabetic macular edema, diabetic retinopathy, macular degeneration, age-related macular degeneration and other diseases of retina and macula lutea. | 06-16-2011 |
20110230455 | AQUEOUS-BASED PHARMACEUTICAL COMPOSITION - An aqueous pharmaceutical composition which is capable of being sprayed into the nasal cavity of an individual and which comprises: (A) a pharmaceutically effective amount of solid particles of medicament which is effective in treating a bodily condition by virtue of its being present on the mucosal surfaces of the nasal cavity; and (B) a suspending agent in an amount effective to maintain said particles dispersed uniformly in the composition and to impart to the composition the following thixotropic properties: (i) the viscosity of the position in unsheared form is relatively high, with the composition being in gel-like form; (ii) as the composition is subjected to shear (shaken) in preparation for spraying, the viscosity of the composition becomes relatively low and such that the composition in the form of a mist flows readily into the nasal passages for deposit on the mucosal surfaces of the nasal cavity; and (D) in deposited form on the mucosal surfaces, the viscosity of the composition is relatively high and such that it resists being cleared from the mucosal surfaces by the inherent mucocillary forces which are present in the nasal cavity, a method of use of the composition and a method for preparation of the composition, including in preferred form the use of anti-inflammatory steroid, for example, triamcinoline acetonide, and an odorless form of the composition. | 09-22-2011 |
20110281834 | Pharmaceutical Formulations for Iontophoretic Delivery of a Corticosteroid - The present invention provides pharmaceutical formulations suitable for iontophoresis that provide enhanced iontophoretic delivery of a corticosteroid to the skin. | 11-17-2011 |
20110288060 | APPARATUS AND PROCESS FOR PRODUCING CRYSTALS - This invention provides an oscillating baffled reactor apparatus for preparing crystalline particles of at least one substance comprising: a reactor vessel; means for supplying a first flowing stream; means for oscillating fluid within the reactor vessel; a plurality of baffles; source of ultrasonic radiation; and means for collecting said particles. | 11-24-2011 |
20110294769 | NITROOXY DERIVATIVES OF GLUCOCORTICOIDS - The invention relates to new steroids nitrooxyderivatives, to topical pharmaceutical formulations thereof, and their use for treating skin or mucosal membrane diseases or disorders. These new steroids nitrooxyderivatives have an improved pharmacological activity and enhanced local tolerability. | 12-01-2011 |
20120028944 | CYCLODEXTRIN NANOTECHNOLOGY FOR OPHTHALMIC DRUG DELIVERY - The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 10% (w/v) to about 99.9% (w/v) of the drug as solid drug/cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in aqueous tear fluid within 24 hours of application to the eye surface. The aqueous eye suspension can be in the form of eye drops, eye gel or eye mist. Further, the invention provides a method for treating a condition of the posterior segment and/or anterior segment of the eye comprising applying to the eye surface, in an amount which delivers to said segment or segments a therapeutically effective amount of a drug suitable for treating said condition, an ophthalmic composition which is as defined above. Nasal compositions and methods and ophthalmic and nasal compositions in powder form are also provided. | 02-02-2012 |
20120035146 | IMPLANTS AND METHODS FOR TREATING INFLAMMATION-MEDIATED CONDITIONS OF THE EYE - Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μg/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 μg/ml dexamethasone for at least about three weeks. | 02-09-2012 |
20120115829 | Low Viscosity, Highly Flocculated Triamcinolone Acetonide Suspensions for Intravitreal Injection - Triamcinolone acetonide suspension compositions are disclosed. The suspension compositions have a relatively low viscosity and are easy to extrude through a 27- or 30-gauge needle but are highly flocculated and easily redispersed. The compositions are particularly suitable for intravitreal injection. | 05-10-2012 |
20120129824 | Pharmaceutical Formulations Containing Corticosteroids for Topical Administration - The potency of a topical corticosteroid in a pharmaceutical formulation is maintained even when the concentration of the corticosteroid is substantially reduced by providing the corticosteroid in a formulation containing a liquid oil component that includes a dicarboxylic acid ester and/or a monocarboxylic acid ester. | 05-24-2012 |
20120142652 | COMPOSITIONS AND METHODS FOR LOCALIZED THERAPY OF THE EYE - Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, and in some cases, less than about 200 nanometers. One example of composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers. | 06-07-2012 |
20120214776 | TOPICAL FORMULATIONS COMPRISING A STEROID - The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders. | 08-23-2012 |
20120220559 | Controlled Release and Taste Masking Oral Pharmaceutical Composition - Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract. | 08-30-2012 |
20120252771 | IMPLANTS AND METHODS FOR TREATING INFLAMMATION-MEDIATED CONDITIONS OF THE EYE - Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μg/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 μg/ml dexamethasone for at least about three weeks. | 10-04-2012 |
20120289490 | COMPOSITIONS AND METHODS FOR ENHANCING CORTICOSTEROID DELIVERY - The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and emulsifiers of at least about 0.70. | 11-15-2012 |
20120309729 | BARRIER COMPOSITION - The invention provides a process for increasing the crystallinity of at least one solid material which is less than 100% crystalline, comprising applying ultrasound to the substantially dry solid material. | 12-06-2012 |
20130029956 | NEW METHOD - The invention provides a novel method of treating respiratory diseases, e.g., pediatric asthma, in a continuing regimen with not more than one daily dose of the drug budesonide using a nebulizer. | 01-31-2013 |
20130053360 | CONTROLLED RELEASE AND TASTE MASKING ORAL PHARMACEUTICAL COMPOSITION - Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract. | 02-28-2013 |
20130059826 | Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid - An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus. | 03-07-2013 |
20130096096 | VISCOUS BUDESONIDE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT - Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention. | 04-18-2013 |
20130143849 | USE OF CICLESONIDE FOR THE TREATMENT OF RESPIRATORY DISEASES - Disclosed herein are novel methods of treating respiratory diseases, and in particular the treatment of asthmatic children. | 06-06-2013 |
20130267488 | PHARMACEUTICAL FORMULATION HAVING NEUROPROTECTIVE ACTIVITY - [Problem] The purpose of the present invention is to provide a neuroprotective agent which is capable of effectively protecting intraocular cells including optic nerves and is effective as a composition for ophthalmic membrane staining in cases where removal of an ophthalmic membrane is carried out. | 10-10-2013 |
20130274233 | MODULATORS OF HEDGEHOG SIGNALING PATHWAY - The invention provides compounds and methods for modulating the Hedgehog signaling pathway. The compounds modulate the translocation and/or accumulation of smoothened to the primary cilia. | 10-17-2013 |
20130296286 | VISCOUS BUDESONIDE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT - Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention. | 11-07-2013 |
20130303498 | Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid - An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus. | 11-14-2013 |
20130303499 | GLUCOCORTICOIDS ATTACHED TO NITRATE ESTERS VIA AN AROMATIC LINKER IN POSITION 21 AND THEIR USE IN OPHTHALMOLOGY - The invention relates to nitrooxy derivatives of fluocinolone acetonide, triamcinolone acetonide, betamethasone and beclomethasone, methods for their preparation, pharmaceutical compositions containing these compounds, and methods of using these compounds and compositions for treating diabetic macular edema, diabetic retinopathy, macular degeneration, age-related macular degeneration and other diseases of retina and macula lutea. | 11-14-2013 |
20130338127 | TRIAMCINOLONE ACETONIDE FORMULATIONS FOR TREATING DERMATITIS AND PSORIASIS - The present invention is drawn to formulations and related methods for treating dermatitis or psoriasis. The formulation can include triamcinolone acetonide, a polymer selected from the group of a poly(2-hydroxyalkylacrylate), a poly(2-hydroxyalkylmethacrylate), and combinations thereof. The formulation also includes a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent. | 12-19-2013 |
20140051671 | PHARMACEUTICAL COMPOSITIONS - Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time. | 02-20-2014 |
20140135302 | CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) BIOMARKERS AND USES THEREOF - Methods, compositions, and kits for predicting whether a subject with chronic obstructive pulmonary disease (COPD) or at risk of developing COPD is likely to have progressive COPD are provided. Methods, compositions, and kits for predicting whether lung function is likely to decline in a subject with COPD or at risk for developing COPD are also provided. | 05-15-2014 |
20140148424 | Pulmonary Pharmaceutical Formulations - The present invention provides improved pharmaceutical formulations for pulmonary delivery having improved chemical and physical stability of the therapeutic, prophylactic or diagnostic agent as compared to formulations known in the art. The improved pharmaceutical formulations of the invention for administration to the respiratory system of a patient for the treatment of a variety of disease conditions comprise a mass of biocompatible particles comprising an active agent, and a hydrogenated starch hydrosylate (HSH). The improvement over the prior art comprises the presence of HSH in the pharmaceutical formulation. The invention further relates to a method of treating diseases comprising administering the pharmaceutical formulations of the present invention to the respiratory system of a patient in need of treatment. | 05-29-2014 |
20140179650 | PHARMACEUTICAL FORMULATION COMPRISING CICLESONIDE - The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to a pharmaceutical (medicament) formulation of glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative thereof. | 06-26-2014 |
20140179651 | CICLESONIDE FOR THE TREATMENT OF AIRWAY DISEASE IN HORSES - The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative or salt thereof, for the treatment of airway disease in horses, such as pulmonary disease, preferably recurrent airway obstruction (RAO), Summer Pasture Associated Obstructive Pulmonary disease (SPAOPD), and inflammatory airway disease (IAD). | 06-26-2014 |
20140187523 | TOPICAL CORTICOSTEROIDS FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT - Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention. | 07-03-2014 |
20140274982 | TOPICAL COMPOSITIONS OF FLUNISOLIDE AND METHODS OF TREATMENT - Provided herein are compositions and methods for treating or preventing a skin disease or skin condition on the skin of a subject by administering a topical flunisolide composition comprising a therapeutically effective amount of flunisolide and a solubilizing agent that solubilizes the flunisolide. | 09-18-2014 |
20140323451 | METHODS FOR ADMINISTERING CORTICOSTEROID FORMULATIONS - Described here are methods for the treatment of respiratory conditions using nebulized corticosteroids. The methods administer a dose of corticosteroid twice a day or more with nebulization times of 5 minutes or less. The faster nebulization times improve patient compliance. The methods also employ a lower corticosteroid dose while achieving therapeutic efficacy similar to commercially available formulations. This results in improved patient safety by reducing the systemic exposure of the corticosteroid. | 10-30-2014 |
20140336160 | NOVEL GLUCOCORTICOLD RECEPTOR AGONISTS - This invention relates to novel glucocorticoid receptor agonists of formula (I): | 11-13-2014 |
20140336161 | PHARMACEUTICAL FORMULATIONS CONTAINING CORTICOSTEROIDS FOR TOPICAL ADMINISTRATION - The potency of a topical corticosteroid in a pharmaceutical formulation is maintained even when the concentration of the corticosteroid is substantially reduced by providing the corticosteroid in a formulation containing a liquid oil component that includes a dicarboxylic acid ester and/or a monocarboxylic acid ester. | 11-13-2014 |
20140336162 | LOCALLY ADMINISTRATED LOW DOSES OF CORTICOSTEROIDS - This invention provides for using a locally delivered low dose of a corticosteroid to treat pain caused by any inflammatory disease including sciatica, herniated disc, stenosis, mylopathy, low back pain, facet pain, osteoarthritis, rheumatoid arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug depot. | 11-13-2014 |
20140349982 | METHODS OF TREATING ULCERATIVE COLITIS - Provided herein are methods of treating and inducing ulcerative colitis in a subject. Also provided are methods of treating subjects with mild to moderate active ulcerative colitis, including ulcerative proctitis and proctosigmoiditis. Also provided are methods of administering budesonide to a subject to treat ulcerative colitis, including ulcerative proctitis and proctosigmoiditis. | 11-27-2014 |
20140349983 | METHOD FOR TREATING ULCERATIVE COLITIS - Provided herein are methods of treating and inducing ulcerative colitis in a subject. Also provided are methods of treating subjects with mild to moderate active ulcerative colitis, including ulcerative proctitis and proctosigmoiditis. Also provided are methods of administering budesonide to a subject to treat ulcerative colitis, including ulcerative proctitis and proctosigmoiditis. | 11-27-2014 |
20150011518 | NON-AQUEOUS LIQUID COMPOSITION - A drug-dissolved non-aqueous liquid composition containing a drug, dioleylphosphatidylcholine, tocopherol and an organic solvent, wherein the blend concentration ratio between the dioleylphosphatidylcholine and the tocopherol falls within the range of 75/25 to 25/75, the blend concentration of the dioleylphosphatidylcholine falls within the range of 15 to 85% (w/w), the blend concentration of the tocopherol falls within the range of 15 to 85% (w/w), and the phase of the non-aqueous liquid composition changes into a non-lamellar liquid crystal upon contact with water, a phosphate buffer, a body fluid, a lacrimal fluid or a vitreous fluid. | 01-08-2015 |
20150025050 | Corticosteroids for the Treatment of Joint Pain - Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production. | 01-22-2015 |
20150105360 | Therapeutic Compositions and Method - This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or addiction induced anxiety and withdrawal side effects as a therapeutic and in concert with a diagnostic. Such addictions could be, but are not limited to, alcohol, drugs, caffeine, sugar, food, nicotine, etc. The present invention further relates to the use of cortisol blockers (GR antagonists) for wound healing and transplants, the prevention or treatment of stress induced osteoporosis and the rapid healing of bone related injuries, and regenerative therapy. | 04-16-2015 |
20150290220 | Pharmaceutical formualtions comprising a Gluococorticosteroid - Sterile formulation comprising glucocorticosteroids, process for the preparation of the sterile formulation and method of using the same are provided. The present invention also relates to sterile formulation comprising budesonide, process for the preparation of the sterile formulation and method of using the same. | 10-15-2015 |
20150313918 | CICLESONIDE FOR THE TREATMENT OF AIRWAY DISEASE IN HORSES - The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative thereof, for the treatment of airway disease in horses, such as pulmonary disease, preferably recurrent airway obstruction (RAO), Summer Pasture Associated Obstructive Pulmonary disease (SPAOPD), and inflammatory airway disease (IAD). | 11-05-2015 |
20150335572 | Medicated Hard Candy Product For Treating Esophageal Inflammation And A Method Using The Same - A medicated hard candy product for treating eosinophilic esophagitis (EoE) is disclosed herein. The medicated hard candy product includes a hard candy base material, the hard candy base material forming a substantially rigid candy product after being heated and permitted to cool for a predetermined time period; and a corticosteroid, the corticosteroid being intermixed with the hard candy base material. The medicated hard candy product is configured to reduce or alleviate esophageal inflammation and/or symptoms associated therewith in an individual when orally administered thereto. In one or more embodiments, the corticosteroid comprises one of: (i) budesonide, (ii) fluticasone, (iii) ciclesonide, (iv) beclomethasone dipropionate, and (v) mometasone furoate. Also, in one or more embodiments, the medicated hard candy product is in the form of a lollipop or lozenge. A method of treating, reducing, or alleviating esophageal inflammation in an individual, which utilizes the medicated hard candy product, is also disclosed herein. | 11-26-2015 |
20150337006 | PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF - The present invention further provides method of preparing nanocrystals or microcrystals of a hydrophobic therapeutic agent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods for treating and/or preventing the signs and/or symptoms of disorders such as blepharitis, meibomian gland dysfunction or skin inflammation or a respiratory disease (e.g., asthma). | 11-26-2015 |
20150377903 | CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) BIOMARKERS AND USES THEREOF - Methods, compositions, and kits for predicting whether a subject with chronic obstructive pulmonary disease (COPD) or at risk of developing COPD is likely to have progressive COPD are provided. Methods, compositions, and kits for predicting whether lung function is likely to decline in a subject with COPD or at risk for developing COPD are also provided. | 12-31-2015 |
20160015634 | AQUEOUS SUSPENSIONS OF CICLESONIDE FOR NEBULISATION - This invention relates to a method for the preparation of sterile aqueous suspensions of ciclesonide by sterilization with moist heat. The invention further relates to pharmaceutical compositions in particular to sterile aqueous suspensions of ciclesonide for administration by nebulization in the prophylaxis and/or treatment of respiratory diseases. | 01-21-2016 |
20160022704 | Fluocinolone Formulations in a Biodegradable Polymer Carrier - Effective treatments of pain and inflammation are provided. Through the administration of an effective amount of fluocinolone at or near a target site, one can reduce, prevent or treat inflammation and pain and autoimmune disorders. In various embodiments, fluocinolone formulations may be provided within biodegradable polymers to reduce, prevent or treat sciatic pain and/or inflammation. In various embodiments, prevent transplant rejection for at least twenty-five days. In some embodiments, the pain relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days. | 01-28-2016 |
20160045434 | COMPOSITION COMPRISING AT LEAST TWO DRY POWDERS OBTAINED BY SPRAY DRYING TO INCREASE THE STABILITY OF THE FORMULATION - The present invention relates to inhalation formulations of drugs in the form of dry powder for inhalation administration deliverable as such with an inhaler and provided with high deliverability, respirability and stability. In particular, the invention relates to a pharmaceutical composition for inhalation in the form of powder comprising at least a first and a second powder, in which at least said first powder contains an active agent in an amount greater than 1% by weight with respect to the weight of said first powder. Both the powders comprise leucine in an amount ranging from 5 to 70% by weight with respect to the weight of each powder and a sugar in an amount ranging from 20 to 90% by weight with respect to the weight of each powder. The composition has a fine particle fraction (FPF) greater than 60% and a delivered fraction (DF) greater than 80. | 02-18-2016 |
20160051568 | CYCLODEXTRIN AND BUDESONIDE DERIVATIVE COMPOSITIONS AND METHODS - The present invention relates to novel and useful pharmaceutical compositions formulated with a cyclodextrin compound and a budesonide derivative for the treatment and/or prevention of pulmonary inflammatory disease. The present invention also relates to a novel and useful analytical technique for the detection and the quantification of HP-β-CD in solution. More specifically, the present invention relates to the use of a validated 1H NMR analysis for the detection and quantification of cyclodextrins directly in pharmaceutical formulations without any extraction or separation steps for liquid formulations. | 02-25-2016 |
20160051683 | EXCIPIENT COMPOSITIONS FOR MUCOADHESIVE PHARMACEUTICAL COMPOSITIONS INCLUDING A SYNERGISTIC COMBINATION OF AMYLOPECTIN, PULLULAN, HYALURONIC ACID, AND XYLOGLUCAN - Excipient compositions including a combination of excipients for mucoadhesive pharmaceutical compositions that improve mucoadhesiveness power, as well as release of and adhesion time of suitable active pharmaceutical ingredients (APIs) are disclosed. The excipient compositions include an aqueous solution with a synergistic combination of polymers, such as, for example amylopectin, pullulan, hyaluronic acid, and tamarind xyloglucan, among others. These polymers have been demonstrated to improve the release of as well as the adhesion time of APIs onto mucosa membrane. Mucoadhesive pharmaceutical compositions that include excipient compositions include suitable APIs, such as, for example analgesics, anesthetics, anthelmintics, anti-allergic agents, anti-fungals, antihistamines, anti-inflammatory agents, antimigraine agents, and hormones, among others. Mucoadhesive pharmaceutical compositions including excipient compositions are employed in the treatment of a plurality of mucous membrane diseases. | 02-25-2016 |
20160069907 | RGMa Fragment Based Diagnostic Assay - Provided are diagnostic assays and method s of using the diagnostic assays for detecting and quantifying RGMa fragments in a sample. The methods may be used detection of the RGMa fragments to monitoring drug treatment and effectiveness of drug treatment in neurodegenerative diseases. | 03-10-2016 |
20160130297 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF - The present invention relates to compounds of Formula (I), | 05-12-2016 |
20160158384 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS - SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length. | 06-09-2016 |
20160185815 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF - The present invention provides compounds of Formula I, | 06-30-2016 |
20160199391 | BERBERINE-URSODEOXYCHOLIC ACID CONJUGATE FOR TREATING THE LIVER | 07-14-2016 |
20170233813 | DIAGNOSTIC METHOD FOR DISTINGUISHING FORMS OF ESOPHAGEAL EOSINOPHILIA | 08-17-2017 |
20220133763 | COMPOSITION CONTAINING NICOTINAMIDE MONONUCLEOTIDE AND MOGROSIDE, AND APPLICATION THEREOF - The present invention belongs to the medical and technical field and provides a medicine or health food composition of nicotinamide mononucleotide and mogroside. In addition, the present invention also provides the preparation method, formulation and application of the composition. | 05-05-2022 |